ASSAY OF MATRIX METALLOPROTEASES TYPE-8 AND TYPE-9 BY ELISA IN HUMAN BREAST-CANCER

DUFFY MJ, BLASER J, DUGGAN C, MCDERMOTT E, OHIGGINS N, FENNELLY JJ, Tschesche H (1995)
BRITISH JOURNAL OF CANCER 71(5): 1025-1028.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
DOI
Autor*in
DUFFY, MJ; BLASER, J; DUGGAN, C; MCDERMOTT, E; OHIGGINS, N; FENNELLY, JJ; Tschesche, HaraldUniBi
Einrichtung
Fakultät für Chemie > Biochemie I
Abstract / Bemerkung
Results from model tumour systems suggest that either increased levels of certain metalloproteases (MMPs) or decreased levels of their inhibitors correlate with metastatic potential. In this study, levels of two MMPs, i.e. MMP-8 and -9, and their inhibitor tissue inhibitor of metalloprotease type 1 (TIMP-1) were measured by enzyme-linked immunosorbent assay in human breast tumours. Levels of MMP-8 and -9 correlated significantly with each other, but neither MMP correlated with urokinase plasminogen activator. Levels of both MMP-8 and -9 were also significantly related to levels of TIMP-1. In contrast, neither MMP correlated with plasminogen activator inhibitor. No relationship was found between MMP-8, MMP-9 or TIMP-1 and either tumour size or metastasis to axillary nodes. MMP-8 and -9 levels were inversely related to levels of oestrogen receptors. MMP-8 but not MMP-9 levels were also inversely correlated with progesterone receptor levels. It is concluded that the assay for MMP-8 and -9 described here will permit the evaluation of these proteases as prognostic markers in cancer.
Stichworte
BREAST CANCER; MMP-9; MMP-8; METALLOPROTEASE; TIMP-1
Erscheinungsjahr
1995
Zeitschriftentitel
BRITISH JOURNAL OF CANCER
Band
71
Ausgabe
5
Seite(n)
1025-1028
ISSN
0007-0920
eISSN
1532-1827
Page URI
https://pub.uni-bielefeld.de/record/1641160

Zitieren

DUFFY MJ, BLASER J, DUGGAN C, et al. ASSAY OF MATRIX METALLOPROTEASES TYPE-8 AND TYPE-9 BY ELISA IN HUMAN BREAST-CANCER. BRITISH JOURNAL OF CANCER. 1995;71(5):1025-1028.
DUFFY, M. J., BLASER, J., DUGGAN, C., MCDERMOTT, E., OHIGGINS, N., FENNELLY, J. J., & Tschesche, H. (1995). ASSAY OF MATRIX METALLOPROTEASES TYPE-8 AND TYPE-9 BY ELISA IN HUMAN BREAST-CANCER. BRITISH JOURNAL OF CANCER, 71(5), 1025-1028. https://doi.org/10.1038/bjc.1995.197
DUFFY, MJ, BLASER, J, DUGGAN, C, MCDERMOTT, E, OHIGGINS, N, FENNELLY, JJ, and Tschesche, Harald. 1995. “ASSAY OF MATRIX METALLOPROTEASES TYPE-8 AND TYPE-9 BY ELISA IN HUMAN BREAST-CANCER”. BRITISH JOURNAL OF CANCER 71 (5): 1025-1028.
DUFFY, M. J., BLASER, J., DUGGAN, C., MCDERMOTT, E., OHIGGINS, N., FENNELLY, J. J., and Tschesche, H. (1995). ASSAY OF MATRIX METALLOPROTEASES TYPE-8 AND TYPE-9 BY ELISA IN HUMAN BREAST-CANCER. BRITISH JOURNAL OF CANCER 71, 1025-1028.
DUFFY, M.J., et al., 1995. ASSAY OF MATRIX METALLOPROTEASES TYPE-8 AND TYPE-9 BY ELISA IN HUMAN BREAST-CANCER. BRITISH JOURNAL OF CANCER, 71(5), p 1025-1028.
M.J. DUFFY, et al., “ASSAY OF MATRIX METALLOPROTEASES TYPE-8 AND TYPE-9 BY ELISA IN HUMAN BREAST-CANCER”, BRITISH JOURNAL OF CANCER, vol. 71, 1995, pp. 1025-1028.
DUFFY, M.J., BLASER, J., DUGGAN, C., MCDERMOTT, E., OHIGGINS, N., FENNELLY, J.J., Tschesche, H.: ASSAY OF MATRIX METALLOPROTEASES TYPE-8 AND TYPE-9 BY ELISA IN HUMAN BREAST-CANCER. BRITISH JOURNAL OF CANCER. 71, 1025-1028 (1995).
DUFFY, MJ, BLASER, J, DUGGAN, C, MCDERMOTT, E, OHIGGINS, N, FENNELLY, JJ, and Tschesche, Harald. “ASSAY OF MATRIX METALLOPROTEASES TYPE-8 AND TYPE-9 BY ELISA IN HUMAN BREAST-CANCER”. BRITISH JOURNAL OF CANCER 71.5 (1995): 1025-1028.

29 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.
Isaacson KJ, Martin Jensen M, Subrahmanyam NB, Ghandehari H., J Control Release 259(), 2017
PMID: 28153760
Proteasome inhibitors: structure and function.
Nunes AT, Annunziata CM., Semin Oncol 44(6), 2017
PMID: 29935898
Reciprocal activation between MMP-8 and TGF-β1 stimulates EMT and malignant progression of hepatocellular carcinoma.
Qin G, Luo M, Chen J, Dang Y, Chen G, Li L, Zeng J, Lu Y, Yang J., Cancer Lett 374(1), 2016
PMID: 26872724
Collagenase expression and activity in the stromal cells from giant cell tumour of bone.
Cowan RW, Mak IW, Colterjohn N, Singh G, Ghert M., Bone 44(5), 2009
PMID: 19442604
Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature.
Köhrmann A, Kammerer U, Kapp M, Dietl J, Anacker J., BMC Cancer 9(), 2009
PMID: 19531263
Real-time reverse-transcription PCR to quantify a panel of 19 genes in breast cancer: relationships with sentinel lymph node invasion.
Révillion F, Lhotellier V, Hornez L, Leroy A, Baranzelli MC, Giard S, Bonneterre J, Peyrat JP., Int J Biol Markers 23(1), 2008
PMID: 18409145
Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer.
Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, Kolacinska A, Morawiec Z, Drzewoski J, Blasiak J., Breast Cancer Res Treat 95(1), 2006
PMID: 16267613
Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast.
Kim HJ, Park CI, Park BW, Lee HD, Jung WH., Yonsei Med J 47(3), 2006
PMID: 16807982
Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA).
Chung DE, Kratz F., Bioorg Med Chem Lett 16(19), 2006
PMID: 16875815
Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation.
Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T, Garnero P., Br J Cancer 95(4), 2006
PMID: 16880790
Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer.
Kubben FJ, Sier CF, Meijer MJ, van den Berg M, van der Reijden JJ, Griffioen G, van de Velde CJ, Lamers CB, Verspaget HW., Br J Cancer 95(6), 2006
PMID: 16940985
Vulnerable plaque: the devil is in the details.
Galis ZS., Circulation 110(3), 2004
PMID: 15262853
Expression of matrix metalloproteinase 8 (MMP-8) and tyrosinase-related protein-1 (TYRP-1) correlates with the absence of metastasis in an isogenic human breast cancer model.
Agarwal D, Goodison S, Nicholson B, Tarin D, Urquidi V., Differentiation 71(2), 2003
PMID: 12641565
Expression of ADAM-9 mRNA and protein in human breast cancer.
O'Shea C, McKie N, Buggy Y, Duggan C, Hill AD, McDermott E, O'Higgins N, Duffy MJ., Int J Cancer 105(6), 2003
PMID: 12767059
Expression of matrix metalloproteinase-9 (gelatinase B) in gouty arthritis and stimulation of MMP-9 by urate crystals in macrophages.
Hsieh MS, Ho HC, Chou DT, Pan S, Liang YC, Hsieh TY, Lan JL, Tsai SH., J Cell Biochem 89(4), 2003
PMID: 12858344
Dynamics of metalloproteinase-2 and -9, TGF-beta, and uPA activities during normoxic vs. hyperoxic alveolarization.
Buckley S, Warburton D., Am J Physiol Lung Cell Mol Physiol 283(4), 2002
PMID: 12225951
Expression of proteinases and inhibitors in human breast cancer progression and survival.
Baker EA, Stephenson TJ, Reed MW, Brown NJ., Mol Pathol 55(5), 2002
PMID: 12354933
Prognostic significance of the combined expression of matrix metalloproteinase-9, urokinase type plasminogen activator and its receptor in breast cancer as measured by Northern blot analysis.
Pacheco MM, Nishimoto IN, Mourão Neto M, Mantovani EB, Brentani MM., Int J Biol Markers 16(1), 2001
PMID: 11288958
Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients.
Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T, Talieri M., Br J Cancer 84(11), 2001
PMID: 11384099
High levels of TIMP-2 correlate with adverse prognosis in breast cancer.
Remacle A, McCarthy K, Noël A, Maguire T, McDermott E, O'Higgins N, Foidart JM, Duffy MJ., Int J Cancer 89(2), 2000
PMID: 10756061
Proteolysis in human breast cancer.
Garbett EA, Reed MW, Stephenson TJ, Brown NJ., Mol Pathol 53(2), 2000
PMID: 10889910
Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients.
Farias E, Ranuncolo S, Cresta C, Specterman S, Armanasco E, Varela M, Lastiri J, Pallotta MG, Bal de Kier Joffe E, Puricelli L., Int J Cancer 89(4), 2000
PMID: 10956415
High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer.
McCarthy K, Maguire T, McGreal G, McDermott E, O'Higgins N, Duffy MJ., Int J Cancer 84(1), 1999
PMID: 9988231
Metalloproteinases and tissue inhibitors of metalloproteinases.
Toi M, Ishigaki S, Tominaga T., Breast Cancer Res Treat 52(1-3), 1998
PMID: 10066076
The relationship between prognostic and predictive factors in the management of breast cancer.
Henderson IC, Patek AJ., Breast Cancer Res Treat 52(1-3), 1998
PMID: 10066087
Role of the matrix metalloproteinase and tissue inhibitors of metalloproteinase families in noninvasive and invasive tumors transplanted in mice with severe combined immunodeficiency.
Furukawa A, Tsuji M, Nishitani M, Kanda K, Inoue Y, Kanayama H, Kagawa S., Urology 51(5), 1998
PMID: 9610608
Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations.
Pacheco MM, Mourão M, Mantovani EB, Nishimoto IN, Brentani MM., Clin Exp Metastasis 16(7), 1998
PMID: 9932604
Hyaluronidase activity in gynaecological cancer tissues with different metastatic forms.
Tamakoshi K, Kikkawa F, Maeda O, Suganuma N, Yamagata S, Yamagata T, Tomoda Y., Br J Cancer 75(12), 1997
PMID: 9192986
Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma.
Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, van Krieken JH, Lamers CB, Verspaget HW., Br J Cancer 74(3), 1996
PMID: 8695357

32 References

Daten bereitgestellt von Europe PubMed Central.

Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.
Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ., Cancer 62(3), 1988
PMID: 3134120
Transforming growth factor beta 1 regulates tissue inhibitor of metalloproteinases-1 expression in differentiated human articular chondrocytes.
Gunther M, Haubeck HD, van de Leur E, Blaser J, Bender S, Gutgemann I, Fischer DC, Tschesche H, Greiling H, Heinrich PC., Arthritis Rheum. 37(3), 1994
PMID: 8129795
Enzyme linked immunosorbent assays (ELISA) for the quantitative determination of human leukocyte collagenase and gelatinase.
Bergmann U, Michaelis J, Oberhoff R, Knauper V, Beckmann R, Tschesche H., J. Clin. Chem. Clin. Biochem. 27(6), 1989
PMID: 2547014
SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages.
Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA, Goldberg GI., J. Biol. Chem. 264(29), 1989
PMID: 2551898
Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family.
Stetler-Stevenson WG, Krutzsch HC, Liotta LA., J. Biol. Chem. 264(29), 1989
PMID: 2793861
Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases.
Alvarez OA, Carmichael DF, DeClerck YA., J. Natl. Cancer Inst. 82(7), 1990
PMID: 2156082
Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue.
Monteagudo C, Merino MJ, San-Juan J, Liotta LA, Stetler-Stevenson WG., Am. J. Pathol. 136(3), 1990
PMID: 2156430
Human neutrophil collagenase. A distinct gene product with homology to other matrix metalloproteinases.
Hasty KA, Pourmotabbed TF, Goldberg GI, Thompson JP, Spinella DG, Stevens RM, Mainardi CL., J. Biol. Chem. 265(20), 1990
PMID: 2164002
Estradiol receptors in human breast carcinomas assayed by use of monoclonal antibodies.
Duffy MJ, O'Siorain L, Waldron B, Smith C., Clin. Chem. 32(10), 1986
PMID: 3530535
Modulation of type-IV collagenase activity and invasive behavior of metastatic human melanoma (A2058) cells in vitro by monoclonal antibodies to type-IV collagenase.
Hoyhtya M, Hujanen E, Turpeenniemi-Hujanen T, Thorgeirsson U, Liotta LA, Tryggvason K., Int. J. Cancer 46(2), 1990
PMID: 2166712
Cathepsin D concentration in breast cancer cytosols: correlation with biochemical, histological, and clinical findings.
Duffy MJ, Brouillet JP, Reilly D, McDermott E, O'Higgins N, Fennelly JJ, Maudelonde T, Rochefort H., Clin. Chem. 37(1), 1991
PMID: 1899058
Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor.
DeClerck YA, Yean TD, Chan D, Shimada H, Langley KE., Cancer Res. 51(8), 1991
PMID: 2009533
Matrix metalloproteinases and their inhibitors in connective tissue remodeling.
Woessner JF Jr., FASEB J. 5(8), 1991
PMID: 1850705
Laminin receptors, collagenase IV and prognosis in node-negative breast cancers.
Daidone MG, Silvestrini R, D'Errico A, Di Fronzo G, Benini E, Mancini AM, Garbisa S, Liotta LA, Grigioni WF., Int. J. Cancer 48(4), 1991
PMID: 1646175
Type-1 plasminogen activator inhibitor in human breast carcinomas.
Reilly D, Christensen L, Duch M, Nolan N, Duffy MJ, Andreasen PA., Int. J. Cancer 50(2), 1992
PMID: 1730515
Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases.
DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM., Cancer Res. 52(3), 1992
PMID: 1732058
Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization.
Pyke C, Ralfkiaer E, Huhtala P, Hurskainen T, Dano K, Tryggvason K., Cancer Res. 52(5), 1992
PMID: 1310643
The role of proteolytic enzymes in cancer invasion and metastasis.
Duffy MJ., Clin. Exp. Metastasis 10(3), 1992
PMID: 1582084
Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia.
Poulsom R, Pignatelli M, Stetler-Stevenson WG, Liotta LA, Wright PA, Jeffery RE, Longcroft JM, Rogers L, Stamp GW., Am. J. Pathol. 141(2), 1992
PMID: 1323219
Cathepsin D in breast cancer: a tissue marker associated with metastasis.
Rochefort H., Eur. J. Cancer 28A(11), 1992
PMID: 1389510
Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas.
Urbanski SJ, Edwards DR, Maitland A, Leco KJ, Watson A, Kossakowska AE., Br. J. Cancer 66(6), 1992
PMID: 1457364
Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase.
Ossowski L., Cancer Res. 52(24), 1992
PMID: 1333882
M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer.
Zucker S, Lysik RM, Zarrabi MH, Moll U., Cancer Res. 53(1), 1993
PMID: 8416738
Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways.
Montgomery AM, De Clerck YA, Langley KE, Reisfeld RA, Mueller BM., Cancer Res. 53(3), 1993
PMID: 8425205
Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue.
Stearns ME, Wang M., Cancer Res. 53(4), 1993
PMID: 7679051
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.
Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H, Graeff H., Breast Cancer Res. Treat. 24(3), 1993
PMID: 8435475
Molecular aspects of tumor cell invasion and metastasis.
Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA., Cancer 71(4), 1993
PMID: 8435813
A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol.
Pujol P, Maudelonde T, Daures JP, Rouanet P, Brouillet JP, Pujol H, Rochefort H., Cancer 71(6), 1993
PMID: 8443752
Expression of activated gelatinase in human invasive breast carcinoma.
Brown PD, Bloxidge RE, Anderson E, Howell A., Clin. Exp. Metastasis 11(2), 1993
PMID: 8444010
92-kd gelatinase is actively expressed by eosinophils and stored by neutrophils in squamous cell carcinoma.
Stahle-Backdahl M, Parks WC., Am. J. Pathol. 142(4), 1993
PMID: 7682768
Activity of type IV collagenases in benign and malignant breast disease.
Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR., Br. J. Cancer 67(5), 1993
PMID: 8494711
Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells.
Khokha R, Waterhouse P, Yagel S, Lala PK, Overall CM, Norton G, Denhardt DT., Science 243(4893), 1989
PMID: 2465572
Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 7734294
PubMed | Europe PMC

Suchen in

Google Scholar